The Prior Authorization Conundrum and What You Can Do About It


Prior authorization (PA) is a time-consuming and costly burden on healthcare providers. With an increase in specialty medication spending, accounting for 70% of total drug spend, PAs are expected to become more stringent and restrictive. Marylou Buyse and Charline Shan share their insight and explore how the vertical integration mergers might impact PA for the better.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.